26-02-2025
Stoke Therapeutics to Present at Upcoming Investor Conferences in March
BEDFORD, Mass., February 26, 2025--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that management will present at the following upcoming investor conferences:
TD Cowen 45th Annual Healthcare ConferenceDate: Wednesday, March 5, 2025Time: 9:50 a.m. ET
Leerink Partners Global Healthcare ConferenceDate: Monday, March 10, 2025Time: 10:40 a.m. ET
Live webcasts of each event, along with archived replays, will be available in the Investors & News section of Stoke's website at
About Stoke TherapeuticsStoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is expected to enter Phase 3 development in 2025. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for the Company's proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit
View source version on
Contacts
Stoke Media & Investor Contacts: Dawn KalmarChief Communications Officerdkalmar@ 781-303-8302
Doug SnowDirector, Communications & Investor RelationsIR@ 508-642-6485
